In vitro antifungal activity of luliconazole (NND-502), a novel imidazole antifungal agent

Journal of Infection and Chemotherapy

Volumn 10, Issue 4, 2004, Pages 216-219

  Uchida, Katsuhisa ^a   Nishiyama, Yayoi ^a   Yamaguchi, Hideyo ^a  

^a TEIKYO UNIVERSITY   (Japan)

Author keywords

Antifungal spectrum; Dermatomycosis; Imidazole; Luliconazole (NND 502)

Indexed keywords

ANTIFUNGAL AGENT; BIFONAZOLE; LANOCONAZOLE; LULICONAZOLE; TERBINAFINE; UNCLASSIFIED DRUG; [4 (2,4 DICHLOROPHENYL) 1,3 DITHIOLAN 2 YLIDENE](1 IMIDAZOLYL)ACETONITRILE;

ANTIFUNGAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; DERMATOMYCOSIS; DERMATOPHYTE; DILUTION; DRUG EFFECT; DRUG SCREENING; DRUG SENSITIVITY; DRUG STRUCTURE; FUNGAL STRAIN; JAPAN; MICROANALYSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SPECIES; YEAST; ZYGOMYCETES;

EID: 4644301871     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-004-0327-1     Document Type: Article

References (11)

1. Niwano Y, Koga H, Kodama H, Kanai K, Miyazako T, Yamaguchi H. Inhibition of sterol 14α-demethylation of Candida albicans with NND-502, a novel optically active imidazole antimycotic agent. Med Mycol 1999;37:321-5.
2. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. 2nd edition. NCCLS document M27-A2, vol 22, no 15. Wayne, PA: National Committee for Clinical Laboratory Standard; 2002.
3. Standardization Committee of the Japanese Society for Medical Mycology. Report of the Standardization Committee of the Japanese Society of Medical Mycology 1995-1997. Jpn J Med Mycol 1999;40:239-57.
4. Padhye AA, Weitzman I. The dermatophytes. In: Ajello L, Hay RJ, editors. Topley & Wilson's microbiology and microbial infection. 7th ed. Vol 4. Medical mycology. London: Arnold; 1998. p. 215-36.
5. Niwano Y, Kuzuhara N, Kodama H, Yoshida M, Miyazaki T, Yamaguchi H. In vitro and in vivo antidermatophyte activities of NND-502, a novel optically active imidazole antimycotic agent. Antimicrob Agents Chemother 1998;42:967-70.
6. Niwano Y, Kuzuhara N, Goto Y, Munechika Y, Kodama H, Kanai K, et al. Efficacy of NND-502, a novel imidazole antimycotic agent, in experimental models of Candida albicans and Aspergillus fumigatus infections. Int J Antimicrob Agents 1999;12:221-8.
7. Uchida K, Nishiyama Y, Tanaka T, Yamaguchi H. In vitro activity of novel imidazole antifungal agent NND-502 against Malassezia species. Int J Antimicrob Agents 2003;21:234-8.
8. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi; proposed standard. M38-P, Vol 18, no 13. Wayne, PA: National Committee for Clinical Laboratory Standards; 1998.
9. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standards. NCCLS document M38-A, Vol 22, no 16. Wayne, PA: National Committee for Clinical Laboratory Standards; 2002.
10. Uchida K, Nishiyama Y, Yokota N, Yamaguchi H. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. J Antibiot 2000;53:1175-81.
11. Uchida K, Yokota N, Yamaguchi H. In vitro antifungal activity of posaconazole against various pathogenic fungi. Int J Antimicrob Agents 2001;18:167-72.